Content about Fixed dose combination

April 4, 2013

FDA grants tentative approval to Aurobindo HIV drug

The Food and Drug Administration has given preliminary approval to a drug made by Aurobindo Pharma for treating HIV infection, the drug maker said.

January 15, 2013

Switching to multi-pill generic HIV treatment could diminish effectiveness, study finds

While replacing a single combination pill for HIV with generics would save the healthcare system money, it could also diminish the effectiveness of treatment, a new study suggests.

November 12, 2012

FDA approves new strength of HIV drug

The Food and Drug Administration has approved a new strength of a drug for HIV made by Johnson & Johnson, the drug maker said.

August 3, 2012

Mylan, Gilead sign HIV/AIDS drug deal

Mylan and Gilead Sciences have made an agreement under which Mylan will have rights to produce and market generic versions of Gilead drugs for HIV and AIDS in developing countries.

July 16, 2012

Gilead's Truvada approved for PrEP

The Food and Drug Administration has approved a drug used to treat HIV for reducing the risk of HIV infection, the agency said Monday.

June 29, 2012

Gilead seeks approval for HIV drug-boosting agent

Drug maker Gilead Sciences has submitted a regulatory approval application to the Food and Drug Administration for a drug designed to increase the blood levels of certain drugs for HIV.

May 23, 2012

FDA approves Mylan generic HIV drug

A generic antiretroviral drug for treating HIV infection has won approval from the Food and Drug Administration.

May 14, 2012

FDA panel recommends approval for experimental Gilead HIV drug

A Food and Drug Administration expert panel has recommended approval of a drug made by Gilead Sciences for treating HIV, the drug maker said Friday.

May 11, 2012

FDA advisory committee recommends PrEP approval for Truvada

An expert panel at the Food and Drug Administration has recommended that the agency approve a drug made by Gilead Sciences for lowering the risk of infection by the virus that causes AIDS.

February 23, 2012

Mylan receives tentative approval for HIV/AIDS drug in developing countries

The Food and Drug Administration has given tentative approval to a division of Mylan for a generic drug for treating HIV and AIDS in children in developing countries.

February 14, 2012

FDA grants priority review to Gilead's Truvada for HIV prevention

The Food and Drug Administration is giving priority review to a drug made by Gilead Sciences that the company is investigating for the prevention of HIV.

January 19, 2012

Gilead receives FDA approval for lower-dose HIV drug in children

The Food and Drug Administration has approved a lower-dose formulation of a drug made by Gilead Sciences for treating HIV in children, the company said.

January 3, 2012

FDA accepts application for Gilead HIV drug

The Food and Drug Administration has accepted a regulatory approval application from Gilead Sciences for a drug to treat HIV, the company said.

October 27, 2011

Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment

Drug makers Bristol-Myers Squibb and Gilead Sciences announced an agreement to develop and commercialize a fixed-dose combination treatment for patients with HIV.

August 11, 2011

FDA approves single-pill HIV drug

The Food and Drug Administration has approved a new single-pill treatment for HIV made by Gilead Sciences and Johnson & Johnson, Gilead said.

June 30, 2011

Physicians urge FDA not to approve Truvada

A group of physicians is urging the Food and Drug Administration not to approve a drug made by Gilead Sciences for the prevention of HIV infection.

January 20, 2011

Under PEPFAR, Matrix gets tentative approval for generic Combivir

The Food and Drug Administration has given tentative approval to an antiretroviral treatment for children with HIV and AIDS under the President’s Emergency Plan for AIDS Relief program.

November 22, 2010

New drug from Gilead may prevent HIV infection, study finds

NEW YORK A daily dose of an anti-retroviral pill appears to prevent HIV infection, according to results of a study conducted by University of California at San Francisco researchers, published in The New England Journal of Medicine on Tuesday.

September 12, 2010

Gilead: 'Quad' anti-retroviral drug as effective as competitor

An investigational treatment for HIV by Gilead Sciences that combines four drugs in one tablet...

July 18, 2010

Kaletra-Isentress therapy for HIV patients as effective as standard treatments, drug makers say

A combination therapy comprising of drugs made by Abbott and Merck is as effective as...